# AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib

> **NCT00853372** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 85 (actual)

## Conditions studied

- Advanced Renal Cell Carcinoma

## Interventions

- **DRUG:** Sunitinib
- **DRUG:** Trebananib

## Key facts

- **NCT ID:** NCT00853372
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-28
- **Primary completion:** 2011-08-08
- **Final completion:** 2019-06-25
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2020-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00853372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00853372, "AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00853372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*